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Abstract: Since its original description in 1994, alcohol septal ablation (ASA) has emerged as a minimally invasive mo-
dality for treatment of hypertrophic obstructive cardiomyopathy compared to surgical myomectomy. This catheter-based 
intervention relies on the injection of absolute alcohol into the septal perforator to induce a controlled infarction of the hy-
pertrophied septum and consequently abolish the dynamic outflow obstruction. This gradient reduction has been corre-
lated with a significant clinical improvement in the patient’s symptomatology and with left ventricular remodeling. The 
procedure has been refined throughout the years, especially with the introduction of myocardial contrast echocardiography 
for localization of the area at risk of infarction and the reduction in the amount of alcohol used. Major complications of 
ASA are uncommon in large referral centers but conduction system disturbances has been the most commonly reported 
complications of ASA with 10% of patients necessitating permanent pacemaker implantation for complete heart block. 
ASA has not been compared to the gold standard surgical myomectomy in a randomized prospective study. We review the 
clinical aspects of this procedure and provide some historical background. 
Key Words: Hypertrophic cardiomyopathy, left ventricular outflow obstruction, alcohol ablation.
INTRODUCTION 
  Hypertrophic cardiomyopathy (HCM) is a genetic cadio-
myopathy inherited as an autosomal dominant trait and char-
acterized by asymmetrical septal hypertrophy unexplained 
by any other cardiac disease. Microscopically, this disease 
process is notable for a distinct abnormal disorderly array of 
myofiber orientation. The disease has a wide spectrum of 
clinical presentation varying from totally asymptomatic indi-
viduals with normal life expectancy to severely symptomatic 
patients with increased mortality due to sudden death or con-
gestive heart failure. The overall prognosis of HCM patients 
is favorable with an annual mortality of about 1% and ad-
verse events are mostly related to sudden cardiac death, ob-
structive symtoms or progressive heart failure. Left ventricu-
lar outflow obstruction is present in 25-30% of patients with 
HCM and constitutes the pathophysiological basis for many 
aspects of the disease. It is also an important prognostic fac-
tor of the disease. In fact, it has been clearly shown that a 
gradient of 30 mmHg or more is associated with an increased 
risk of disease progression, congestive heart failure, stroke 
and death. While the treatment of obstructive HCM has 
largely relied on pharmacologic management of the disease 
with beta-blockers and calcium channel blockers, a small but 
important subgroup of patients are refractory to medical 
therapy. Surgical myectomy and percutaneous alcohol septal 
ablation have proven efficacy in the symptomatic manage-
ment of this drug-refractory population. Alcohol septal abla-
tion was developed as a less invasive approach to reduce left 
ventricular outflow obstruction by inducing a partially con-
trolled infarct of the basal septum with resultant scar forma-
tion and left ventricular remodeling.  
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INDICATIONS FOR SEPTAL REDUCTION 
  Septal reduction therapies are largely reserved for the 
subgroup of patients with obstructive HCM who continue to 
experience significant symptomatology despite maximized 
medical therapy: limited functional capacity secondary to 
exertional dyspnea and chest pain classified as NYHA III-IV 
or CCS III-IV. In addition, the ACC/ESC recommends that 
two additional selection criteria be employed in selecting 
patients for this procedure 1) septal hypertrophy of 18mm or 
more and 2) resting or provocable gradient of 50 mmHg or 
more [1]. However, with the increased experience and rela-
tive safety of ASA, these criteria have been relaxed and the 
procedure is now used to treat an increasing number of pa-
tients with obstructive symptoms. In fact, in a recent system-
atic review of almost 3000 patients undergoing ASA by 
Alam et al., the mean NYHA class was 2.9 (±0.01), and only 
51-53% percent were on beta-blocker or calcium channel 
blocker therapy [2].  
  The preprocedural evaluation of candidates for ASA 
should include a rigorous clinical and echocardiographic 
investigation of comorbidities and other cardiac anomalies. 
A careful review of the patients’ medical therapy should be 
undertaken to assess the potential for symptomatic improve-
ment by optimization of this regimen. Moreover, an evalua-
tion for concomitant abnormalities which warrant definitive 
surgical therapy is necessary. These abnormalities include 
discrete subaortic stenosis, severe coronary artery disease 
and structural abnormalities of the mitral valve. In particular 
mitral valvular apparatus abnormalities are common in these 
patients (7-10%) and include: abnormal insertion of the pap-
illary muscle into the anterior mitral valve leaflet and ab-
normal fibrous attachment or fusion of the papillary muscles 
to the septum or LV free wall both of which result in mid-
cavitary fixed obstruction [3, 4]. Careful echocardiographic 
evaluation of the mitral regurgitant jet timing and direction is 
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PROCEDURE DETAILS 
  Percutaneous alcohol septal ablation was introduced in 
1994 as a less invasive alternative to surgical myomectomy 
and was originally targeted to a population of symptomatic 
patients who were thought to be poor surgical candidates. 
The procedure has undergone significant technical refine-
ments most notable of which is the introduction of myocar-
dial contrast echocardiographic localization of the target 
area.  
  After obtaining arterial access, the procedure is usually 
initiated with a reevaluation of the patient’s hemodynamics 
and re-measurement of the intracavitary gradient. This is 
performed through simultaneous pressure measurement in 
the left ventricle with an end-hole catheter and the aorta. 
Physiologic provocation of the gradient is then assessed with 
the Valsalva maneuver and checking for the Brockenbrough 
sign by inducing a ventricular extrasystole. Venous access, 
usually through the femoral vein, is also obtained and a tem-
porary transvenous pacemaker is inserted into the RV apex. 
Coronary angiography is then performed to exclude severe 
coronary disease and to locate the first septal perforator. 
Usually this vessel arises from the proximal LAD, however 
it might have a separate takeoff from the left main, or branch 
from the left circumflex, ramus intermedius, or the right 
coronary. Uncommonly, a distinct first septal perforator can-
not be located which obviates the procedure’s feasibility. 
The septal perforator is then engaged with an over-the-wire 
balloon, the lumen of which serves to inject contrast and 
alcohol. The balloon is then inflated and a selective angi-
ogram is performed to exclude its encroachment onto the 
LAD. Angiographic contrast may also be injected through 
the balloon lumen to ensure no spill of the contrast back into 
the LAD. During inflation, a continuous monitoring of the 
gradient might reveal a significant reduction indicating a 
favorable target vessel and usually portends a good response 
to ASA [4].  
  Due to anatomical variation of the septal perforator, the 
area supplied by this vessel might include a variable amount 
of myocardial tissue that might not only involve the hyper-
trophied basal septum but also the right ventricular septum 
and even the LV apex [5]. In that respect, evaluation of the 
area at risk by myocardial contrast echocardiography is con-
sidered a key aspect for the localization of the ablation which 
ideally should only be localized to the proximal septum at 
the point of contact with the anterior mitral leaflet. Echocar-
diographic contrast is injected thru the balloon and intrapro-
cedural two-dimensional transthoracic echocardiogram is 
performed to visualize the perfusion area prior to alcohol 
injection [6, 7]. Patients with a large area at risk or who have 
a significant involvement of the right ventricle have a higher 
complications rate including complete atrioventricular block 
[7, 8]. In cases where the septal perforator supplies large 
territories, lower doses of alcohol may be used. Also, if the 
vessel bifurcates, the branch supplying the basal septum 
should be used. 
  After localizing the target vessel, the transvenous pace-
maker is checked for capture and intravenous analgesia is 
administered. Then a slow injection of absolute alcohol is 
performed through the target vessel and a gradient reassess-
ment is performed to demonstrate an initial partial response 
defined. After deflation of the balloon, a final angiogram is 
performed to ensure the patency of the LAD (this usually 
shows an occluded septal perforator at the site of injection).  
  The dose as well as the rate of alcohol injection during 
ASA have been the subject of continuous reevaluation and 
vary between institutions. Original studies used 3-4ml injec-
tions however in a recent randomized controlled trial of 
thirty four patients undergoing ASA, a lower dose (less than 
2 ml) of alcohol injected resulted in similar reductions in the 
outflow gradient and symptomatic improvement at six-
month follow up [9]. The amount of alcohol injected has 
been correlated with the area of necrosis (peak CKMB) and 
has been shown to be an independent predictor of ASA com-
plications and post-procedural mortality [10]. Moreover a 
slower rate of alcohol injection has been correlated with a 
decreased incidence of complete heart block in recent series 
[4, 11, 12].  
STRUCTURAL REMODELING AND HEMODY-
NAMIC EFFECTS OF ASA 
  Although ASA is followed by an immediate decrease of 
the outflow gradient, most of the acute diminution likely 
represents stunning and is pathophysiologically different 
from the more delayed phenomenon which is a result of aki-
nesis and thining of the basal septum. The immediate aboli-
tion of the outflow gradient may be followed by a recurrence 
of the gradient 1 to 3 days after ASA. Then, a permanent and 
more substantial reduction in the gradient (mean LVOT gra-
dient from 65 to 31 mmHg [2]) progressively develops 
within 3 to 12 months after the procedure and is a direct re-
sult of scar formation, thinning, and left ventricular remodel-
ing [13-15]. ASA has been also associated with a significant 
decrease and even abolition of mitral regurgitation on long 
term follow-up [16].Cardiac magnetic resonance imaging 
(CMR) and strain rate imaging have been used to evaluate 
the effect of remodeling on the LV systolic function. These 
Fig. (1). Apical four-chamber views illustrating the use of myocar-
dial contrast echocardiography to determine area at risk during 
ASA: injection into the first septal perforator results in enhance-
ment of the proximal basal septum. (adapted with permission from 
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studies showed a significant decrease in myocardial mass 
and LV wall thickness both in the infarcted and non infarcted 
areas at early and midterm follow up after ASA [17-19]. 
Moreover, a small decrease in the ejection fraction is noted 
in these follow up studies with a paradoxical increase in 
global systolic indices (shortening index and Tei index) [17, 
20]. Diastolic function has been extensively studied in pa-
tients with HCM and follow up studies of post-ASA patients 
have shown a significant and sustained improvement in 
echocardiographic diastolic parameters [20, 21]. In a recent 
study by Jassal et al., all patients had a pseudonormal or an 
impaired relaxation pattern at baseline along with left atrial 
dilation. They showed significant improvement in E-wave
deceleration time, isovolumic relaxation time, early diastolic
mitral lateral annular velocity (E'), mitral inflow propagation
velocity, ratio of transmitral early LV filling velocity (E) to 
early diastolic Doppler tissue imaging of the mitral annulus 
(E/E'), and E/Vp were observed on long term follow up one 
and two years following successful ASA [22].  
CLINICAL OUTCOMES AND POTENTIAL COM-
PLICATIONS AFTER ASA 
  ASA has been associated with a favorable clinical re-
sponse in short and intermediate-term follow-up studies. In a 
recent systematic review of 42 studies involving 2959 pa-
tients, Alam et al. demonstrated a significant improvement in 
heart failure symptoms with mean NYHA class from 2.9 to 
1.2 as well as angina with mean CCS class from 1.9 to 0.4 at 
1 year follow-up [2]. Peak oxygen consumption increased 
from 17.8 to 23.6 ml/kg per minute and mean exercise ca-
pacity on a treadmill from 325.3 to 437.5 seconds [2].  
  Complications of ASA, although rare in high volume 
centers, occur in the early post-procedural period and include 
LAD dissection, coronary artery spasm, cardiac tamponade, 
cardiogenic shock, pulmonary embolism and stroke. Most 
commonly, however, ASA causes a transient or permanent 
disruption of the conduction system: first degree AV block 
develops in 53% of patients while RBBB block in 46% and 
complete heart block (CHB) requiring permanent pacemaker 
(PPM) implantation in 10.5% of patients. Interestingly, CHB  
may be a transient phenomenon in 10 to 46% of patients with 
recovery within the first 24 hours [23, 24], while few pa-
tients might develop CHB up to nine days after ASA [11, 
25]. This may have an important impact on post-procedural 
care. Specifically the length of hospital stay that varies ac-
cording to institutional protocol from at least 24-48 hours up 
to five days of CCU monitoring [4, 24, 26]. Several studies 
evaluated determinants of complete heart block after ASA in 
an effort to identify a high risk group that would benefit from 
a PPM implantation prior to the procedure. While age >55, 
female gender, bolus injection of alcohol, injection of more 
than one septal perforator, volume of alcohol injection and 
lack of use myocardial contrast echocardiographic localiza-
tion are all potential factors, only the presence of LBBB on 
baseline ECG has been persistently identified as a strong 
predictor of CHB [11, 23, 27, 28]. Faber et al. proposed a 
scoring system based on electrocardiographic markers of 
abnormal AV conduction (PQ interval, QRS duration and 
baseline heart rate), the severity of the LVOT gradient, re-
versibility of CHB, and timing of the SGOT peak. Based on 
this scoring system, three risk groups could be identified: 
low risk patients can be discharged after short term monitor-
ing (48 hours), a high risk group where an elective PPM im-
plantation should be considered, and an intermediate group 
for whom prolonged monitoring and expectant management 
are warranted [24]. Based on the present knowledge, it is still 
unclear if prophylactic PPM implantation is indicated for 
patients with LBBB at baseline and larger scale prospective 
evaluation is needed to answer this question.  
  Ventricular arrhythmias have been reported and include 
ventricular fibrillation (2.2%) [2] and less commonly sus-
tained ventricular tachycardia (VT) [29-32]. Typically, they 
develop in the early post-procedural period and are self-
limited but few patients present with VT up to 3 weeks after 
ASA. The mechanism of these arrhythmias is controversial 
and has been suggested to be secondary to reentry around the 
MI-induced scar; however the arrhythmogenic potential of 
the myofibrillar disarray characteristic of HCM can’t be ex-
cluded. All patients reported in the literature with sustained  
Fig. (2). Transthoracic echocardiogram in hypertrophic obstructive cardiomyopathy: continous wave Doppler across the LVOT (A) before 
ASA indicating severe obstruction with a dynamic gradient of 96 mmHg and (B) 6 months after ASA with resolution of the obstruction. 196 Current Cardiology Reviews, 2008, Vol. 4, No. 3 El Masry and Breall 
VT after ASA underwent ICD implantation hence adding a 
therapeutic challenge to the management of these patients.  
  Early mortality occurring within the first 30 days after 
ASA has been reported to be 1.5% (0-5%) and results usu-
ally from hemodynamic collapse due to ventricular failure or 
tamponade, ventricular fibrillation or LAD dissection [2]. 
Unfortunately, few reports address the long term safety and 
outcomes of ASA especially late all-cause mortality. Kuhn et 
al. reported on a single center experience with ASA where 
644 patients were followed for up to 10 years. In their report, 
they described a significant decrease in the incidence of 
complications correlating with decreasing alcohol dosage 
(from a mean of 2.9 ml to 0.8 ml). In fact, in-hospital mortal-
ity decreased from 1.8% to 0.6% and was mostly ascribed to 
non-cardiac causes of death [10]. It is clear however that an 
improved expertise might be an integral part in the refine-
ment of the procedure with subsequent decrease of the com-
plication rate. After hospital discharge, limited data indicates 
an annual mortality rate of 3.2% which is comparable to the 
natural history of high-risk HOCM patients.  
COMPARISON OF ASA AND SEPTAL MYECTOMY 
  Since its introduction by Sigwart in 1994, ASA has been 
performed in thousands of patients with good short term re-
sults. Acute anatomical changes after ASA and myomec-
tomy have been evaluated by cardiac MRI; ASA results in a 
larger area of tissue necrosis (16±7 grams compared to 6±4 
grams) often involving a transmural infarct with varying 
location and depth at the junction of the anterior and inferior 
segments of the basal septum [33]. Some patients have had 
extension of the infarction into the right ventricular side of 
the septum with associated residual gradient on follow-up 
and less favorable symptomatic relief [34]. Myomectomy 
results in a more localized resection of the LV aspect of the 
basal septum as compared to the deeper scar of ASA offering 
a potential explanation of the association of ASA with 
RBBB and of the myomectomy with LBBB. Aside of these 
morphological differences, myomectomy is associated with a 
lower risk of complete AV block necessitating permanent 
pacemaker implantation (5% vs. 17%) [35] and an immediate 
clinical benefit although at the cost of a higher risk of strokes 
and a longer recovery period postoperatively [36].  
  Few reports compared the clinical outcomes of ASA to 
surgical myomectomy and no comparison of long term out-
comes has been performed. In a recent meta-analysis of three 
retrospective studies including 171 patients [37-40], both 
interventions had comparable effect on interventricular sep-
tal thickness reduction, left ventricular end-diastolic dimen-
sion increase and NYHA class improvement [35]. However, 
there was a small but significant difference in the relief of 
the LVOT gradient: from 76.0 to 15.7 mmHg in ASA group 
compared to a decrease from 74.7 to 9.4 mmHg in the myo-
mectomy group (p<0.05) [35]. It is difficult to predict any 
role of this difference in affecting the clinical outcomes after 
ASA and this question needs to be evaluated prospectively 
with longer follow-up period. Moreover, all reports compar-
ing ASA and myomectomy usually involved an older cohort 
with more comorbidities for patients receiving the percuta-
neous therapy and it remains unclear if these factors may 
interact with the treatment effect.  
CONCULSIONS 
  ASA has developed as a safe and attractive modality to 
treat patients with HCM whose symptoms are refractory to 
optimal medical therapy with negative inotropic agents. The 
procedure has been refined over the past decade since its 
development with steadily improving outcomes and reduced 
complications especially PPM implantation. However, con-
cerns over the higher risk of complete AV block and devel-
opment of a potentially arrhythmogenic scar after ASA have 
been raised [41]. The gold standard for HCM has been clas-
sically considered the surgical approach that has been time-
tested over the past forty years, although many interventional 
cardiologists consider ASA as a first line intervention due to 
its ease of performance and less invasive nature. Either pro-
cedure is best performed by an experienced operator. The 
feasibility of comparing both modalities in a randomized 
controlled trial has been questionned due to the low fre-
quency of the disease and the low event rates after these in-
terventions [42]. Alternatively, a multicenter prospective 
evaluation of non-randomized patients with long term fol-
low-up would be reasonable to resolve this controversy. 
Meanwhile, ASA is a reasonable therapeutic option espe-
cially in older patients with significant comorbidities (espe-
cially lung disease) and a favorable coronary anatomy in the 
absence of mitral valve disease.  
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